title: E2 treated rep5

city: Torino

first: Raffaele

middle: A

last: Calogero

state: To

address: Via Nizza 52

department: Molecular Biotechnology Center

country: Italy

institute: University of Torino

description: 1 nM E2 treated cells

hyb_protocol: Target hybridization were performed according to Affymetrix instructions

scan_protocol: All the hybridizations, washing, stainings and scanning procedures were done using a Genechip Affymetrix station (FS 450, Scanner 3000) as recommended by the manufacturer

data_processing: CEL files were loaded in oneChannelGUI Bioconductor package 1.30.0. RMA and sketch quantile normalization were applied.

source_name: adipocytes

label_protocol: Biotinylated cRNA target preparation was performed according to Affymetrix instructions

growth_protocol: Human preadipocytes and differentiated mature adipocytes were cultured in high-glucose - phenol red free Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 µg/mL streptomycin and 1 mM L-Glutamine.

extract_protocol: Total RNA was isolated from differentiated adipocytes, untreated or treated with BPA or E2, using Trizol Reagent in accordance with the manufacturer's protocol.

treatment_protocol: Differentiated human mature adipocytes (1x106 cells) were treated for 24 hours with different BPA concentrations (10nM)  and/or E2 (1 nM) as indicated in each experiment by diluting directly in the culture medium a BPA or E2 stock 100% ethanol solutions starting from BPA 10 µM and E2 1 µM.  Adipocytes treated with 0.1% ethanol were used as control. Cells were grown in humidified atmosphere containing 5% CO2 at 37°C.

value: 1 nM E2 treated cells

value: adipocyte


title: E2 treated rep4

status: Public on Jul 09 2015

type: RNA

description: 1 nM E2 treated cells

label: biotin

molecule: total RNA

organism: Homo sapiens

tag: treatment

tag: cell type


title: E2 treated rep3

description: 1 nM E2 treated cells


title: E2 treated rep2

description: 1 nM E2 treated cells


title: BPA treated rep5

description: 10 nM BPA treated cells

value: 10 nM BPA treated cells


title: E2 treated rep1

description: 1 nM E2 treated cells


title: TD control (Sample_13)

type: genomic

city: Toronto

first: Lucy

last: Osborne

state: ON

address: 7360 Medical Sciences Building, 1 Kings College Circle

department: Medicine

country: Canada

institute: University of Toronto

description:
blood sample from typically developing child
genomic DNA from whole blood sample

hyb_protocol: Sandard Illumina protocol using bisulfite converted genomic DNA

scan_protocol: Standard protocol using the Illumina iScan SQ scanner

data_processing: Image files were pre-processed using GenomeStudio (v2011.1) methylation module (v1.9.0) using background correction and Illumina normalization

label: Cy3 and Cy5

molecule: genomic DNA

source_name: whole blood

label_protocol: Standard Illumina protocol

extract_protocol: Genomic DNA was extracted from freshly drawn blood samples using either 5 prime DNA extraction, AllPrep DNA/RNA mini kit or QIAamp DNA blood mini kit using standard protocols

tag: group

value: TD control

tag: tissue

value: whole blood


title: KMS-34_rep2_261891

city: Washington

first: Robert

last: Hawley

state: DC

address: 2300 I Street NW, Suite 431

department: Anatomy and Regenerative Biology

country: USA

institute: George Washington University

description: Gene expression data from KMS-34 multiple myeloma cells

hyb_protocol: Hybridization of cRNA on Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays was performed by Expression Analysis, Inc.

scan_protocol: Scanning of GeneChip arrays was performed by Expression Analysis, Inc.

data_processing: The data were analyzed with GeneSpring software (Agilent Technologies) using default settings and the RMA normalization and summarization algorithm.

source_name: KMS-34 multiple myeloma cells

label_protocol: Biotinylated cRNA was prepared by Expression Analysis, Inc. (Durham, NC).

growth_protocol: Cells for gene expression profiling were cultured in RPMI 1640 with GlutaMAX (Life Technologies) supplemented with 4% fetal bovine serum.

extract_protocol: Total RNA was isolated with the miRNeasy mini kit (Qiagen).

treatment_protocol: KMS-11/Cfz and KMS-34/Cfz cells were profiled for gene expression after 1 week of growth in the absence of carfilzomib together with parental KMS-11 and KMS-34 cells which had not been selected in the drug.

tag: cell line

value: multiple myeloma


title: Dup7 (Sample_45)

description:
Dup7 blood sample
genomic DNA from whole blood sample


title: KMS-34_rep3_261890


title: TD control (Sample_15)


title: Dup7 (Sample_44)


title: BPA treated rep3

description: 10 nM BPA treated cells


title: Dup7 (Sample_42)


title: Dup7 (Sample_40)


title: TD control (Sample_14)


title: KMS-11_rep3_261896

description: Gene expression data from KMS-11 multiple myeloma cells

source_name: KMS-11 multiple myeloma cells


title: BPA treated rep1

description: 10 nM BPA treated cells


title: BPA treated rep2

description: 10 nM BPA treated cells


title: Dup7 (Sample_37)


title: WS (Sample_32)

description:
WS blood sample
genomic DNA from whole blood sample

value: WS


title: Dup7 (Sample_43)


title: WS (Sample_33)


title: WS (Sample_31)


title: KMS-11_rep1_261898


title: WS (Sample_35)


title: WS (Sample_34)


title: Dup7 (Sample_36)


title: Dup7 (Sample_41)


title: TD control (Sample_11)


title: KMS-34_rep1_261892


title: untreated rep5

description: untreated

value: untreated


title: Dup7 (Sample_38)


title: Dup7 (Sample_39)


title: untreated rep2

description: untreated


title: TD control (Sample_10)


title: KMS-34/Cfz_rep3_261895

description: Gene expression data from KMS-34/Cfz multiple myeloma cells resistant to 12 nM carfilzomib


title: untreated rep4

description: untreated


title: WS (Sample_30)


title: untreated rep3

description: untreated


title: untreated rep1

description: untreated


title: TD control (Sample_8)


title: KMS-34/Cfz_rep1_261893

source_name: KMS-34/Cfz multiple myeloma cells resistant to 12 nM carfilzomib


title: KMS-34/Cfz_rep2_261894


title: IL-2-9

city: Miami

first: Thomas

middle: R

last: Malek

state: FL

address: 1600 NW 10th Avenue

department: Microbiology/Immunology

institute: University of Miami

description: FACS purified Tregs

hyb_protocol: Biotinylated cRNA was hybridized to Affymetrix Gene  ST1.0  arrays

scan_protocol: Image analysis was performed using the Affymetrix Command Console Software (AGCC).

data_processing: Resulting data were normalized with the RMA method using software at GeneSifter (Seattle, WA). Two -group comparisons of the transformed data of 9 independent biological replicates were performed using ANOVA applying the Benjamini Hochberg correction for false positives.

source_name: regulatory T cell with IL-2

label_protocol: 100-200 ng RNA was used in a single round of linear RNA probe amplification and labeling using NuGEN V2 amplification system  (NuGEN, San Carlos, CA, USA)

extract_protocol: Total RNA was isolated using TRizol and further purified with RNAeasy Minikit (QIAGEN). RNA quantity and qulaity was confirmned by analysis with a Agilent 2100 Bioananalyzer.

treatment_protocol: Human treg were FACS purified and cultured for 24 hr in the presence or absence of IL-2 (100 u/ml)

value: peripheral blood

value: Tregs

tag: media culture

value: with IL-2 100u/ml


title: BPA treated rep4

description: 10 nM BPA treated cells


title: KMS-11/Cfz_rep3_261901

description: Gene expression data from KMS-11/Cfz multiple myeloma cells resistant to 12 nM carfilzomib


title: IL-2-8

description: FACS purified Tregs


title: KMS-11/Cfz_rep2_261899

source_name: KMS-11/Cfz multiple myeloma cells resistant to 12 nM carfilzomib


title: Activated microglia

city: Fukuoka

first: Ryo

last: Yamasaki

state: Fukuoka

address: 3-1-1 Maidashi, Higashi-Ku

department: Neurology

country: Japan

institute: Kyushu University

hyb_protocol: cRNA was hybridized to a 60K 60-mer oligomicroarray (SurePrint G3 Mouse Gene Expression Microarray 8x60K ; Agilent Technologies) according to the manufacturer's instructions.

scan_protocol: The hybridized microarray slides were scanned using an Agilent scanner. The relative hybridization intensities and background hybridization values were calculated using Feature Extraction Software version 9.5.1.1 (Agilent Technologies).

data_processing: The scanned images were analyzed with Feature Extraction Software 9.5.1.1 (Agilent) using default parameters to obtain background subtracted and spatially detrended Processed Signal intensities.  The raw signal intensities and flags for each probe were calculated from the hybridization intensities and spot information according to the procedures recommended by Agilent Technologies using the Flag criteria in the GeneSpring Software. In addition, the raw signal intensities of two samples were log2-transformed and normalized by the quantile algorithm with the Bioconductor.

organism: Mus musculus

source_name: microglia

label_protocol: cRNA was amplified and labelled using a Low input Quick Amp Labelling Kit (Agilent Technologies).

extract_protocol: Total RNA was isolated from tissues using TRIzol Reagent (nitrogen) and purified using SV Total RNA Isolation System (Promega)

value: microglia

tag: genotype/variation

value: Atopic diathesis


title: TD control (Sample_9)


title: KMS-11/Cfz_rep1_261900


title: IL-2-6

description: FACS purified Tregs


title: TD control (Sample_5)


title: IL-2-7

description: FACS purified Tregs


title: IL-2-5

description: FACS purified Tregs


title: 14 weeks WD Macrophages Rep 3

city: Albany

first: Antonio

last: Paul

state: NY

address: Center for Cardiovascular Sciences

institute: Albany Medical College

description: Gene expression data from foam cells in atherosclerotic lesions of apolipoprotein E-deficient mice fed regular chow for 8 weeks and western diet 14 weeks prior to sacrifice.

hyb_protocol: 15 μg of fragmented RNA were hybridized to Mouse Genome 430 2.0 Arrays (Affymetrix). Washing, staining and scanning were performed following Affymetrix standard protocols.

scan_protocol: Standard Affymetrix Protocol

data_processing: Normalized and Modeled using Standard Affymetrix Settings. Data was normalized with dChip 2008_05.

label: Biotin

source_name: Foam cells in atherosclerotic lesions of apolipoprotein E-deficient mice fed regular chow for 8 weeks and western diet 14 weeks prior to sacrifice.

label_protocol: 15 μg of amplified RNA were biotin-labeled with with TURBO Labeling Kit (Applied Biosystems) following the manufacturer's instructions.

extract_protocol: Macrophages in atherosclerotic lesions were harvested by laser capusre microdissection. RNA was extracted with PicoPure RNA Isolation Kit (ap;lied Biosystems). RNA was amplified with RiboAMP HS RNA Amplification Kit (Applied Biosystems)

tag: strain

value: Foam cells

value: ApoE-/-


title: 14 weeks WD Macrophages Rep 4


title: TD control (Sample_7)


title: TD control (Sample_12)


title: IL-2-4

description: FACS purified Tregs


title: 14 weeks WD Macrophages Rep 5


title: IL-2-3

description: FACS purified Tregs


title: IL-2-2

description: FACS purified Tregs


title: 14 weeks WD Macrophages Rep 2


title: 2 weeks WD Macrophages Rep 5

description: Gene expression data from foam cells in atherosclerotic lesions of apolipoprotein E-deficient mice fed regular chow for 20 weeks and western diet two weeks prior to sacrifice.

source_name: Foam cells in atherosclerotic lesions of apolipoprotein E-deficient mice fed regular chow for 20 weeks and western diet two weeks prior to sacrifice.


title: Normal microglia

value: control


title: TD control (Sample_4)


title: TD control (Sample_3)


title: IL-2-1

description: FACS purified Tregs


title: 14 weeks WD Macrophages Rep 1


title: WS (Sample_29)


title: 2 weeks WD Macrophages Rep 4


title: Media-8

description: FACS purified Tregs

source_name: regulatory T cell without IL-2

value: without IL-2


title: 2 weeks WD Macrophages Rep 3


title: 2 weeks WD Macrophages Rep 1


title: Media-6

description: FACS purified Tregs


title: WS (Sample_28)


title: KMS-11_rep2_261897


title: Media-9

description: FACS purified Tregs


title: Media-7

description: FACS purified Tregs


title: Media-5

description: FACS purified Tregs


title: 2 weeks WD Macrophages Rep 2


title: WS (Sample_23)


title: Media-4

description: FACS purified Tregs


title: CHOW Macrophages Rep 4

description: Gene expression data from foam cells in atherosclerotic lesions of apolipoprotein E-deficient mice fed regular chow for 22 weeks.

source_name: Foam cells in atherosclerotic lesions of apolipoprotein E-deficient mice fed regular chow for 22 weeks.


title: WS (Sample_24)


title: CHOW Macrophages Rep 2


title: CHOW Macrophages Rep 3


title: Media-2

description: FACS purified Tregs


title: ICL-1

status: Public on Jul 08 2015

type: other

city: Stanford

first: Jacob

last: Rosenberg

state: CA

address: 269 Campus Drive, CCSR 2240

institute: Stanford

hyb_protocol: Arrays were first blocked in 7% fetal bovine serum (FBS) (Omega Scientific, Cat#FB-11) in PBS plus 0.1% Tween (Sigma-Aldrich, Cat#P1279) (PBST) for one hour at 4°C rocking, and then washed three times in PBST. Arrays were probed for one hour with plasma diluted 1:150 in 30% FBS 1% PBST, rocking at 4°C. Arrays were subjected to three five minute washes in 1% PBST. Plasma reactivity was detected using an Alexafluor 647-conjugated goat anti-human IgG secondary antibody (Jackson, Cat # 109-605-044) diluted to 2.5 µg/ml in 30% FCS 1% PBST for 45 minutes. Arrays were washed three times in PBST and dried under negative pressure.

scan_protocol: Arrays were scanned using an Axon digital scanning system (Molecular Devices, Sunnyvale, CA)

data_processing: Local background was subtracted from feature mean fluorescence intensity. Means were calculated across replicates, and these values were used for analysis.

molecule: other

source_name: Plasma

label_protocol: Goat anti-Human IgG conjugated to AF647 (Jackson Immunoresearch, West Grove, PA)

growth_protocol: Plasma was collected by centrifuging whole blood, stored at -80C, and thawed for analysis.

treatment_protocol: Plasma was diluted into probing buffer as described

tag: sample type

value: plasma

tag: clinical disease

value: Idiopathic CD4 Lymphopenia


title: WS (Sample_27)


title: CID-14

value: Combined Immunodeficiency


title: APS-1 3-6


title: WS (Sample_22)


title: CID-13


title: CID-11


title: WS (Sample_19)


title: CHOW Macrophages Rep 1


title: Media-1

description: FACS purified Tregs


title: CID-9


title: CID-3


title: CID-8


title: CID-2


title: OS-12

value: Omenn Syndrome


title: OS-11


title: Media-3

description: FACS purified Tregs


title: OS-10


title: WS (Sample_21)

value: whole blood


title: WS (Sample_20)


title: LS-5

value: Leaky SCID


title: WS (Sample_17)

value: WS


title: WS (Sample_26)


title: ctr4 1 9mo M

value: Healthy Control


title: ctr8 27 3yr F


title: ctr6 12 12mo F


title: ctr36 120 8yr F


title: ctr32 29 4yr M


title: ctr30 6 2yr M


title: CID-12


title: WS (Sample_25)


title: WS (Sample_16)


title: WS (Sample_18)


title: ctr34 5 4yr M


title: ctr28 7 2yr M


title: ctr26 31 3yr M


title: TD control (Sample_2)

value: TD control


title: secondary alone pad 2

description: Secondary alone arrays are used to normalize other samples and so processed data are not provided. The provided GPR file would allow a user to reproduce our analysis.

organism: synthetic construct

source_name: empty (secondary antibody)

value: secondary antibody


title: LS-6


title: ctr24 3 9mo M


title: ctr22 4 9mo M


title: ctr18 _ 25yo M


title: ctr14 32 4yr F


title: secondary alone pad 1


title: ctr16 2 2yr F


title: ctr12 21 2yr F


title: TD control (Sample_6)


title: CHOW Macrophages Rep 5


title: ctr10 28 4yr M


title: TD control (Sample_1)


title: Best_Prolidase_fibros_P6_1

city: Seattle

first: Michael

last: Katze

state: WA

address: Rosen Building 960 Republican St.

department: Microbiology

institute: University of Washington

hyb_protocol: The Agilent One-Color Microarray-Based Gene Expression Analysis Protocol was followed for hybridization and array washing. Two hundred fifty ng of each RNA sample was hybridized to one Agilent 4X44K human array.

scan_protocol: Dry slides were scanned on an Agilent DNA microarray scanner (Model G2505B) using the XDR setting.

data_processing: Raw images were analyzed using the Agilent Feature Extraction software (version 9.5.3.1) and the GE1-v5_95_Feb07 extraction protocol. All arrays were required to pass Agilent QC flags. Extracted raw data were background corrected using the norm-exp method and quantile normalized using Agi4x44PreProcess and RMA Bioconductor packages.

source_name: PI_Study molecule_cell type_patient ID_replicate

label_protocol: The Agilent One-Color Microarray-Based Gene Expression Analysis Protocol was followed for the Cy3-cDNA probe preparation, followed by RNeasy column purification (QIAGEN, Valencia, CA).  Dye incorporation and cRNA yield were checked with the Nanodrop ND-2000 Spectrophotometer.

growth_protocol: Prolidase-deficient patients were enrolled on an NIAID Institutional Review Board (IRB) approved protocol (10-H-0126; NCT00001355) or in an Italian Ethical Committee approved  study (Prot22/CE, Pavia). Fibroblasts were generated from punch biopsies that were dissected into several pieces and incubated at 37C, with shaking, for 1h in 9mL of 1mg/mL collagenase II and 1mL of 2.5U/mL dispase (Life Technologies). The tissue pieces were then placed under a cover slip in a culture dish containing 20% FBS/DMEM until fibroblasts growing out from the explanted tissue could be transferred for standard cell culture. Fibroblasts were routinely monitored for mycoplasma contamination, were not used past passage 10 and were generally assayed at 48 hours post plating. Samples were collected by lysing cells in TRIzol buffer (Life Technologies).

extract_protocol: All TRIzol lysates were processed simultaneously: they were phase-separated, and RNA was isolated from the aqueous phase (diluted 2 fold with RLT buffer) using Qiagen RNeasy Mini columns and the manufacturer’s recommended protocol (Qiagen). RNA quality was assessed on an Agilent 2100 Bioanalyzer using the nanochip format, and only intact RNA was used for microarray analyses.

treatment_protocol: Not applicable.

value: Fibroblast cells

tag: pepd status

value: Normal


title: Best_Prolidase_fibros_P170_1


title: Best_Prolidase_fibros_P170_2


title: Best_Prolidase_fibros_P169_1


title: Best_Prolidase_fibros_P45_1

value: Deficient


title: Best_Prolidase_fibros_P45_3


title: Best_Prolidase_fibros_P43_1


title: FELODIPINE_OCI-Ly3_12_TH001_NG_110210_01_H10

city: New York

first: Andrea

last: Califano

address: 1130 St. Nicholas Avenue, Rm. 906

institute: Columbia University

description:
tumor cell line
Therasis_TH001_NG3_20110210_H10

hyb_protocol: Following fragmentation with a buffered zinc solution  (Fragmentation Reagent, Ambion), 7.5 ug of labelled cRNA were hybridized on HG-U219 arrays in 120ul volume/well. The GeneTitan Hybridization, Wash and Stain kit (Affymetrix) was used for preparing hybridization mixes and processing of 96-array plates on the GeneTitan Instrument (Affymetrix).

scan_protocol: Human Genome U219 array plate was processed in GeneTitan according to manufacturer's instructions

data_processing: The data were analyzed with RMA method in R

label_protocol: 300ng of each of the samples with RIN value >7 were converted to biotinylated cRNA with the Illumina TotalPrep-96 RNA Amplification Kit (Ambion) using a standard T7-based amplification protocol

growth_protocol: Cell lines were cultured in Iscove’s Modified Dulbecco Medium supplemented with 10% fetal bovine serum at 37°C in a 5% CO2 atmosphere.

extract_protocol: Total RNA was isolated with the RNAqueous-96 Automated Kit (Ambion) on the Janus automated liquid handling system (Perkin Elmer Inc.), quantified by NanoDrop 6000 spectrophotometer and quality checked by Agilent Bioanalyzer.

treatment_protocol: A stock concentration of the IC20 at 24 hour was created by dilution in DMSO. Cells were treated with the 24hr IC20 of each of the compounds for 6, 12, and 24hrs at 37°C, 5% CO2 under humidified conditions. 0.2% DMSO vehicle treated samples were used as controls.

tag: compound treated

value: FELODIPINE

tag: time

value: 12 hrs


title: Best_Prolidase_fibros_ATTC_2


title: Best_Prolidase_fibros_P43_2


title: Best_Prolidase_fibros_P46_1


title: RIBAVIRIN_OCI-Ly3_12_TH001_NG_110210_01_H08

description:
tumor cell line
Therasis_TH001_NG3_20110210_H08

value: RIBAVIRIN


title: Best_Prolidase_fibros_ATTC_1


title: Best_Prolidase_fibros_P169_2


title: Best_Prolidase_fibros_P9_1


title: Best_Prolidase_fibros_P45_2


title: Best_Prolidase_fibros_P46_2


title: DMSO_OCI-Ly3_12_TH001_NG_110210_01_H12

description:
tumor cell line
Therasis_TH001_NG3_20110210_H12

value: DMSO


title: Best_Prolidase_fibros_P9_2


title: PENTOXIFYLLINE_OCI-Ly3_12_TH001_NG_110210_01_H09

description:
tumor cell line
Therasis_TH001_NG3_20110210_H09

value: PENTOXIFYLLINE


title: Best_Prolidase_fibros_P6_2


title: TINIDAZOLE_OCI-Ly3_12_TH001_NG_110210_01_H06

description:
tumor cell line
Therasis_TH001_NG3_20110210_H06

value: TINIDAZOLE


title: INDAPAMIDE_OCI-Ly3_12_TH001_NG_110210_01_H04

description:
tumor cell line
Therasis_TH001_NG3_20110210_H04

value: INDAPAMIDE


title: Best_Prolidase_fibros_P9_4


title: ALPROSTADIL_OCI-Ly3_12_TH001_NG_110210_01_H11

description:
tumor cell line
Therasis_TH001_NG3_20110210_H11

value: ALPROSTADIL


title: PROMAZINE.HYDROCHLORIDE_OCI-Ly3_12_TH001_NG_110210_01_H05

description:
tumor cell line
Therasis_TH001_NG3_20110210_H05


title: Best_Prolidase_fibros_ATTC_3


title: Best_Prolidase_fibros_P9_3


title: Gemcitabine_OCI-Ly3_12_TH001_NG_110210_01_H07

description:
tumor cell line
Therasis_TH001_NG3_20110210_H07

value: Gemcitabine


title: GEMFIBROZIL_OCI-Ly3_12_TH001_NG_110210_01_H03

description:
tumor cell line
Therasis_TH001_NG3_20110210_H03

value: GEMFIBROZIL


title: VALPROIC.ACID_OCI-Ly3_12_TH001_NG_110210_01_G12

description:
tumor cell line
Therasis_TH001_NG3_20110210_G12


title: DMSO_OCI-Ly3_12_TH001_NG_110210_01_H01

description:
tumor cell line
Therasis_TH001_NG3_20110210_H01


title: DIMERCAPROL_OCI-Ly3_12_TH001_NG_110210_01_G09

description:
tumor cell line
Therasis_TH001_NG3_20110210_G09

value: DIMERCAPROL


title: Toremifene_OCI-Ly3_12_TH001_NG_110210_01_G11

description:
tumor cell line
Therasis_TH001_NG3_20110210_G11

value: Toremifene


title: Butoconazole.nitrate_OCI-Ly3_12_TH001_NG_110210_01_G10

description:
tumor cell line
Therasis_TH001_NG3_20110210_G10


title: DAPSONE_OCI-Ly3_12_TH001_NG_110210_01_H02

description:
tumor cell line
Therasis_TH001_NG3_20110210_H02

value: DAPSONE


title: Cladribine_OCI-Ly3_12_TH001_NG_110210_01_F12

description:
tumor cell line
Therasis_TH001_NG3_20110210_F12

value: Cladribine


title: SULFAMERAZINE_OCI-Ly3_12_TH001_NG_110210_01_F05

description:
tumor cell line
Therasis_TH001_NG3_20110210_F05

value: SULFAMERAZINE


title: GLIPIZIDE_OCI-Ly3_12_TH001_NG_110210_01_E09

description:
tumor cell line
Therasis_TH001_NG3_20110210_E09

value: GLIPIZIDE


title: TRANEXAMIC.ACID_OCI-Ly3_12_TH001_NG_110210_01_G01

description:
tumor cell line
Therasis_TH001_NG3_20110210_G01


title: GRAMICIDIN_OCI-Ly3_12_TH001_NG_110210_01_G07

description:
tumor cell line
Therasis_TH001_NG3_20110210_G07

value: GRAMICIDIN


title: NIZATIDINE_OCI-Ly3_12_TH001_NG_110210_01_F11

description:
tumor cell line
Therasis_TH001_NG3_20110210_F11

value: NIZATIDINE


title: ALTRETAMINE_OCI-Ly3_12_TH001_NG_110210_01_G06

description:
tumor cell line
Therasis_TH001_NG3_20110210_G06

value: ALTRETAMINE

value: 12 hrs


title: INDOMETHACIN_OCI-Ly3_12_TH001_NG_110210_01_G03

description:
tumor cell line
Therasis_TH001_NG3_20110210_G03

value: INDOMETHACIN


title: AMIODARONE.HYDROCHLORIDE_OCI-Ly3_12_TH001_NG_110210_01_F09

description:
tumor cell line
Therasis_TH001_NG3_20110210_F09


title: HYDROCHLOROTHIAZIDE_OCI-Ly3_12_TH001_NG_110210_01_G04

description:
tumor cell line
Therasis_TH001_NG3_20110210_G04

value: HYDROCHLOROTHIAZIDE


title: ETHOPROPAZINE.HYDROCHLORIDE_OCI-Ly3_12_TH001_NG_110210_01_F04

description:
tumor cell line
Therasis_TH001_NG3_20110210_F04


title: IMATINIB_OCI-Ly3_12_TH001_NG_110210_01_E12

description:
tumor cell line
Therasis_TH001_NG3_20110210_E12

value: IMATINIB


title: ENOXACIN_OCI-Ly3_12_TH001_NG_110210_01_F06

description:
tumor cell line
Therasis_TH001_NG3_20110210_F06

value: ENOXACIN


title: Auranofin_OCI-Ly3_12_TH001_NG_110210_01_F08

description:
tumor cell line
Therasis_TH001_NG3_20110210_F08

value: Auranofin


title: TAMOXIFEN.CITRATE_OCI-Ly3_12_TH001_NG_110210_01_G05

description:
tumor cell line
Therasis_TH001_NG3_20110210_G05


title: APOMORPHINE.HYDROCHLORIDE_OCI-Ly3_12_TH001_NG_110210_01_F02

description:
tumor cell line
Therasis_TH001_NG3_20110210_F02


title: CHLORMEZANONE_OCI-Ly3_12_TH001_NG_110210_01_E10

description:
tumor cell line
Therasis_TH001_NG3_20110210_E10

value: CHLORMEZANONE


title: CEFIXIME_OCI-Ly3_12_TH001_NG_110210_01_F10

description:
tumor cell line
Therasis_TH001_NG3_20110210_F10

value: CEFIXIME


title: Docetaxel_OCI-Ly3_12_TH001_NG_110210_01_E07

description:
tumor cell line
Therasis_TH001_NG3_20110210_E07

value: Docetaxel


title: CLEMASTINE_OCI-Ly3_12_TH001_NG_110210_01_G02

description:
tumor cell line
Therasis_TH001_NG3_20110210_G02

value: CLEMASTINE


title: CYTARABINE_OCI-Ly3_12_TH001_NG_110210_01_G08

description:
tumor cell line
Therasis_TH001_NG3_20110210_G08

value: CYTARABINE


title: GALLAMINE.TRIETHIODIDE_OCI-Ly3_12_TH001_NG_110210_01_F03

description:
tumor cell line
Therasis_TH001_NG3_20110210_F03


title: TENIPOSIDE_OCI-Ly3_12_TH001_NG_110210_01_E08

description:
tumor cell line
Therasis_TH001_NG3_20110210_E08

value: TENIPOSIDE


title: PYRITHIONE.ZINC_OCI-Ly3_12_TH001_NG_110210_01_F07

description:
tumor cell line
Therasis_TH001_NG3_20110210_F07


title: Irinotecan.Hydrochloride_OCI-Ly3_12_TH001_NG_110210_01_E11

description:
tumor cell line
Therasis_TH001_NG3_20110210_E11


title: FOLIC.ACID_OCI-Ly3_12_TH001_NG_110210_01_F01

description:
tumor cell line
Therasis_TH001_NG3_20110210_F01


title: ETOPOSIDE_OCI-Ly3_12_TH001_NG_110210_01_E06

description:
tumor cell line
Therasis_TH001_NG3_20110210_E06

value: ETOPOSIDE


title: DYCLONINE.HYDROCHLORIDE_OCI-Ly3_12_TH001_NG_110210_01_E03

description:
tumor cell line
Therasis_TH001_NG3_20110210_E03


title: ECONAZOLE.NITRATE_OCI-Ly3_12_TH001_NG_110210_01_E01

description:
tumor cell line
Therasis_TH001_NG3_20110210_E01


title: MITOMYCIN.C_OCI-Ly3_12_TH001_NG_110210_01_E02

description:
tumor cell line
Therasis_TH001_NG3_20110210_E02


title: NITROFURAZONE_OCI-Ly3_12_TH001_NG_110210_01_E04

description:
tumor cell line
Therasis_TH001_NG3_20110210_E04

value: NITROFURAZONE


title: BRINZOLAMIDE_OCI-Ly3_12_TH001_NG_110210_01_D10

description:
tumor cell line
Therasis_TH001_NG3_20110210_D10

value: BRINZOLAMIDE


title: ISOPROPAMIDE.IODIDE_OCI-Ly3_12_TH001_NG_110210_01_D04

description:
tumor cell line
Therasis_TH001_NG3_20110210_D04


title: FULVESTRANT_OCI-Ly3_12_TH001_NG_110210_01_C10

description:
tumor cell line
Therasis_TH001_NG3_20110210_C10

value: FULVESTRANT


title: TOPOTECAN.HYDROCHLORIDE_OCI-Ly3_12_TH001_NG_110210_01_D08

description:
tumor cell line
Therasis_TH001_NG3_20110210_D08


title: AZATHIOPRINE_OCI-Ly3_12_TH001_NG_110210_01_D02

description:
tumor cell line
Therasis_TH001_NG3_20110210_D02

value: AZATHIOPRINE


title: DEFEROXAMINE.MESYLATE_OCI-Ly3_12_TH001_NG_110210_01_D03

description:
tumor cell line
Therasis_TH001_NG3_20110210_D03

value: 12 hrs


title: Itraconazole_OCI-Ly3_12_TH001_NG_110210_01_D11

description:
tumor cell line
Therasis_TH001_NG3_20110210_D11

value: Itraconazole


title: THIOTHIXENE_OCI-Ly3_12_TH001_NG_110210_01_E05

description:
tumor cell line
Therasis_TH001_NG3_20110210_E05

value: THIOTHIXENE


title: CLOZAPINE_OCI-Ly3_12_TH001_NG_110210_01_D06

description:
tumor cell line
Therasis_TH001_NG3_20110210_D06

value: CLOZAPINE


title: TRIMETHADIONE_OCI-Ly3_12_TH001_NG_110210_01_D09

description:
tumor cell line
Therasis_TH001_NG3_20110210_D09

value: TRIMETHADIONE


title: SULINDAC_OCI-Ly3_12_TH001_NG_110210_01_D05

description:
tumor cell line
Therasis_TH001_NG3_20110210_D05

value: SULINDAC


title: TRIFLUOPERAZINE.HYDROCHLORIDE_OCI-Ly3_12_TH001_NG_110210_01_C06

description:
tumor cell line
Therasis_TH001_NG3_20110210_C06


title: TROGLITAZONE_OCI-Ly3_12_TH001_NG_110210_01_C11

description:
tumor cell line
Therasis_TH001_NG3_20110210_C11

value: TROGLITAZONE


title: VINCRISTINE.SULFATE_OCI-Ly3_12_TH001_NG_110210_01_D07

description:
tumor cell line
Therasis_TH001_NG3_20110210_D07


title: DIGITOXIN_OCI-Ly3_12_TH001_NG_110210_01_C08

description:
tumor cell line
Therasis_TH001_NG3_20110210_C08

value: DIGITOXIN


title: FLURBIPROFEN_OCI-Ly3_12_TH001_NG_110210_01_C04

description:
tumor cell line
Therasis_TH001_NG3_20110210_C04

value: FLURBIPROFEN


title: VORINOSTAT_OCI-Ly3_12_TH001_NG_110210_01_D12

description:
tumor cell line
Therasis_TH001_NG3_20110210_D12

value: VORINOSTAT


title: MEBENDAZOLE_OCI-Ly3_12_TH001_NG_110210_01_C01

description:
tumor cell line
Therasis_TH001_NG3_20110210_C01

value: MEBENDAZOLE


title: MELPHALAN_OCI-Ly3_12_TH001_NG_110210_01_D01

description:
tumor cell line
Therasis_TH001_NG3_20110210_D01

value: MELPHALAN


title: ACETOHEXAMIDE_OCI-Ly3_12_TH001_NG_110210_01_C09

description:
tumor cell line
Therasis_TH001_NG3_20110210_C09

value: ACETOHEXAMIDE


title: DACTINOMYCIN_OCI-Ly3_12_TH001_NG_110210_01_C07

description:
tumor cell line
Therasis_TH001_NG3_20110210_C07

value: DACTINOMYCIN


title: SULFACETAMIDE_OCI-Ly3_12_TH001_NG_110210_01_C05

description:
tumor cell line
Therasis_TH001_NG3_20110210_C05

value: SULFACETAMIDE


title: RIFABUTIN_OCI-Ly3_12_TH001_NG_110210_01_C12

description:
tumor cell line
Therasis_TH001_NG3_20110210_C12

value: RIFABUTIN


title: ACRISORCIN_OCI-Ly3_12_TH001_NG_110210_01_C02

description:
tumor cell line
Therasis_TH001_NG3_20110210_C02

value: ACRISORCIN


title: ESTRADIOL_OCI-Ly3_12_TH001_NG_110210_01_C03

description:
tumor cell line
Therasis_TH001_NG3_20110210_C03

value: ESTRADIOL

value: 12 hrs


title: RISPERIDONE_OCI-Ly3_12_TH001_NG_110210_01_B12

description:
tumor cell line
Therasis_TH001_NG3_20110210_B12

value: RISPERIDONE


title: TIOCONAZOLE_OCI-Ly3_12_TH001_NG_110210_01_B09

description:
tumor cell line
Therasis_TH001_NG3_20110210_B09

value: TIOCONAZOLE


title: PICROPODOPHYLLIN_OCI-Ly3_12_TH001_NG_110210_01_B10

description:
tumor cell line
Therasis_TH001_NG3_20110210_B10

value: PICROPODOPHYLLIN


title: Mometasone.furoate_OCI-Ly3_12_TH001_NG_110210_01_B11

description:
tumor cell line
Therasis_TH001_NG3_20110210_B11


title: VINBLASTINE.SULFATE_OCI-Ly3_12_TH001_NG_110210_01_B08

description:
tumor cell line
Therasis_TH001_NG3_20110210_B08


title: TRIFLUPROMAZINE.HYDROCHLORIDE_OCI-Ly3_12_TH001_NG_110210_01_B07

description:
tumor cell line
Therasis_TH001_NG3_20110210_B07


title: THIOGUANINE_OCI-Ly3_12_TH001_NG_110210_01_B05

description:
tumor cell line
Therasis_TH001_NG3_20110210_B05

value: THIOGUANINE


title: SULFASALAZINE_OCI-Ly3_12_TH001_NG_110210_01_B06

description:
tumor cell line
Therasis_TH001_NG3_20110210_B06

value: SULFASALAZINE


title: ERGOCALCIFEROL_OCI-Ly3_12_TH001_NG_110210_01_B03

description:
tumor cell line
Therasis_TH001_NG3_20110210_B03

value: ERGOCALCIFEROL


title: FENOFIBRATE_OCI-Ly3_12_TH001_NG_110210_01_B01

description:
tumor cell line
Therasis_TH001_NG3_20110210_B01

value: FENOFIBRATE


title: MICONAZOLE.NITRATE_OCI-Ly3_12_TH001_NG_110210_01_B04

description:
tumor cell line
Therasis_TH001_NG3_20110210_B04


title: PINDOLOL_OCI-Ly3_12_TH001_NG_110210_01_A06

description:
tumor cell line
Therasis_TH001_NG3_20110210_A06

value: PINDOLOL


title: CHLOROXINE_OCI-Ly3_12_TH001_NG_110210_01_A07

description:
tumor cell line
Therasis_TH001_NG3_20110210_A07

value: CHLOROXINE


title: DMSO_OCI-Ly3_12_TH001_NG_110210_01_A12

description:
tumor cell line
Therasis_TH001_NG3_20110210_A12

value: DMSO


title: Metixene.hydrochloride_OCI-Ly3_12_TH001_NG_110210_01_A11

description:
tumor cell line
Therasis_TH001_NG3_20110210_A11


title: SULFINPYRAZONE_OCI-Ly3_12_TH001_NG_110210_01_A05

description:
tumor cell line
Therasis_TH001_NG3_20110210_A05

value: SULFINPYRAZONE


title: NISOLDIPINE_OCI-Ly3_12_TH001_NG_110210_01_A09

description:
tumor cell line
Therasis_TH001_NG3_20110210_A09

value: NISOLDIPINE


title: CLOMIPHENE.CITRATE_OCI-Ly3_12_TH001_NG_110210_01_A03

description:
tumor cell line
Therasis_TH001_NG3_20110210_A03


title: ROSIGLITAZONE_OCI-Ly3_12_TH001_NG_110210_01_B02

description:
tumor cell line
Therasis_TH001_NG3_20110210_B02

value: ROSIGLITAZONE


title: TUBOCURARINE.CHLORIDE_OCI-Ly3_12_TH001_NG_110210_01_A10

description:
tumor cell line
Therasis_TH001_NG3_20110210_A10


title: TINIDAZOLE_OCI-Ly3_24_TH001_NG_101128_02_H06

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_H06

value: TINIDAZOLE

value: 24 hrs


title: FELODIPINE_OCI-Ly3_24_TH001_NG_101128_02_H10

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_H10

value: FELODIPINE


title: MITOXANTHRONE.HYDROCHLORIDE_OCI-Ly3_12_TH001_NG_110210_01_A08

description:
tumor cell line
Therasis_TH001_NG3_20110210_A08

value: 12 hrs


title: SULCONAZOLE.NITRATE_OCI-Ly3_12_TH001_NG_110210_01_A02

description:
tumor cell line
Therasis_TH001_NG3_20110210_A02


title: HEXACHLOROPHENE_OCI-Ly3_12_TH001_NG_110210_01_A04

description:
tumor cell line
Therasis_TH001_NG3_20110210_A04

value: HEXACHLOROPHENE


title: ALPROSTADIL_OCI-Ly3_24_TH001_NG_101128_02_H11

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_H11

value: ALPROSTADIL


title: GEMFIBROZIL_OCI-Ly3_24_TH001_NG_101128_02_H03

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_H03

value: GEMFIBROZIL


title: PENTOXIFYLLINE_OCI-Ly3_24_TH001_NG_101128_02_H09

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_H09

value: PENTOXIFYLLINE


title: DMSO_OCI-Ly3_12_TH001_NG_110210_01_A01

description:
tumor cell line
Therasis_TH001_NG3_20110210_A01


title: DMSO_OCI-Ly3_24_TH001_NG_101128_02_H12

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_H12


title: Gemcitabine_OCI-Ly3_24_TH001_NG_101128_02_H07

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_H07

value: Gemcitabine


title: PROMAZINE.HYDROCHLORIDE_OCI-Ly3_24_TH001_NG_101128_02_H05

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_H05


title: DAPSONE_OCI-Ly3_24_TH001_NG_101128_02_H02

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_H02

value: DAPSONE


title: INDAPAMIDE_OCI-Ly3_24_TH001_NG_101128_02_H04

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_H04

value: INDAPAMIDE


title: Butoconazole.nitrate_OCI-Ly3_24_TH001_NG_101128_02_G10

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_G10


title: VALPROIC.ACID_OCI-Ly3_24_TH001_NG_101128_02_G12

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_G12


title: DMSO_OCI-Ly3_24_TH001_NG_101128_02_H01

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_H01


title: DIMERCAPROL_OCI-Ly3_24_TH001_NG_101128_02_G09

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_G09

value: DIMERCAPROL


title: ALTRETAMINE_OCI-Ly3_24_TH001_NG_101128_02_G06

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_G06

value: ALTRETAMINE


title: CEFIXIME_OCI-Ly3_24_TH001_NG_101128_02_F10

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_F10

value: CEFIXIME


title: Toremifene_OCI-Ly3_24_TH001_NG_101128_02_G11

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_G11

value: Toremifene


title: TAMOXIFEN.CITRATE_OCI-Ly3_24_TH001_NG_101128_02_G05

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_G05


title: HYDROCHLOROTHIAZIDE_OCI-Ly3_24_TH001_NG_101128_02_G04

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_G04

value: HYDROCHLOROTHIAZIDE


title: CYTARABINE_OCI-Ly3_24_TH001_NG_101128_02_G08

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_G08

value: CYTARABINE


title: ETHOPROPAZINE.HYDROCHLORIDE_OCI-Ly3_24_TH001_NG_101128_02_F04

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_F04


title: ENOXACIN_OCI-Ly3_24_TH001_NG_101128_02_F06

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_F06

value: ENOXACIN


title: GRAMICIDIN_OCI-Ly3_24_TH001_NG_101128_02_G07

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_G07

value: GRAMICIDIN

value: 24 hrs


title: INDOMETHACIN_OCI-Ly3_24_TH001_NG_101128_02_G03

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_G03

value: INDOMETHACIN


title: TRANEXAMIC.ACID_OCI-Ly3_24_TH001_NG_101128_02_G01

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_G01


title: Auranofin_OCI-Ly3_24_TH001_NG_101128_02_F08

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_F08

value: Auranofin


title: APOMORPHINE.HYDROCHLORIDE_OCI-Ly3_24_TH001_NG_101128_02_F02

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_F02


title: IMATINIB_OCI-Ly3_24_TH001_NG_101128_02_E12

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_E12

value: IMATINIB


title: CLEMASTINE_OCI-Ly3_24_TH001_NG_101128_02_G02

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_G02

value: CLEMASTINE


title: CHLORMEZANONE_OCI-Ly3_24_TH001_NG_101128_02_E10

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_E10

value: CHLORMEZANONE


title: NIZATIDINE_OCI-Ly3_24_TH001_NG_101128_02_F11

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_F11

value: NIZATIDINE


title: GALLAMINE.TRIETHIODIDE_OCI-Ly3_24_TH001_NG_101128_02_F03

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_F03


title: PYRITHIONE.ZINC_OCI-Ly3_24_TH001_NG_101128_02_F07

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_F07


title: GLIPIZIDE_OCI-Ly3_24_TH001_NG_101128_02_E09

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_E09

value: GLIPIZIDE


title: SULFAMERAZINE_OCI-Ly3_24_TH001_NG_101128_02_F05

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_F05

value: SULFAMERAZINE


title: Cladribine_OCI-Ly3_24_TH001_NG_101128_02_F12

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_F12

value: Cladribine


title: FOLIC.ACID_OCI-Ly3_24_TH001_NG_101128_02_F01

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_F01


title: AMIODARONE.HYDROCHLORIDE_OCI-Ly3_24_TH001_NG_101128_02_F09

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_F09


title: TENIPOSIDE_OCI-Ly3_24_TH001_NG_101128_02_E08

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_E08

value: TENIPOSIDE


title: Irinotecan.Hydrochloride_OCI-Ly3_24_TH001_NG_101128_02_E11

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_E11


title: MITOMYCIN.C_OCI-Ly3_24_TH001_NG_101128_02_E02

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_E02


title: Docetaxel_OCI-Ly3_24_TH001_NG_101128_02_E07

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_E07

value: Docetaxel


title: VORINOSTAT_OCI-Ly3_24_TH001_NG_101128_02_D12

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_D12

value: VORINOSTAT


title: ETOPOSIDE_OCI-Ly3_24_TH001_NG_101128_02_E06

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_E06

value: ETOPOSIDE


title: ECONAZOLE.NITRATE_OCI-Ly3_24_TH001_NG_101128_02_E01

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_E01


title: DYCLONINE.HYDROCHLORIDE_OCI-Ly3_24_TH001_NG_101128_02_E03

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_E03


title: BRINZOLAMIDE_OCI-Ly3_24_TH001_NG_101128_02_D10

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_D10

value: BRINZOLAMIDE


title: MSC cyto rep2

city: San Francisco

last: Matthay

state: California

address: 513 Parnassus Ave

department: CVRI

institute: UCSF

description: gene expression of MSC stimulated

hyb_protocol: The cRNA was hybridized to U133A Affymetrix microarray chips that contained 16–20 unique 25-mer oligonucleotide probes for ∼14,500 human genes plus corresponding 12–16 probes with a single nucleotide change (mismatch control). Hybridizations were performed with cRNA prepared from co-cultured human AT II and human MSCs experiments.

scan_protocol: genechips were scanned using the Hewlett-Packard GeneArray Scanner.

data_processing: Affymetrix Microarray Suite 5.0 was used to quantify and analyze mRNA content for expressed genes. The Microarray Suite software uses Wilcoxon's signed rank tests to test whether a transcript is detectable on the array and the probability of a significant change between arrays, assigning P values and a change call (increase, decrease, no change) for each probe. When more than one probe set was present for the same gene, data were combined to provide a mean value. Fold-stimulation results are expressed as mean ± SD. All analyses were performed using the R/Bioconductor software (http://www.bioconductor.org).

source_name: MSC

label_protocol: RNA was converted to biotin-labeled cRNA using Affymetrix reagents and protocol (www.affymetrix.com).  hybridized to U133A Affymetrix microarray chips that contained 16–20 unique 25-mer oligonucleotide probes for ∼14,500 human genes plus corresponding 12–16 probes with a single nucleotide change (mismatch control). Hybridizations were performed with cRNA prepared from co-cultured human AT II and human MSCs experiments.

growth_protocol: Human ATII cells were grown into a tight monolayer at 96 ~120 h. The the cells were washed and serum-starved with plain medium for 24 h. MSCs were then plated in the bottom compartment of the transwell at a density of 250,000 cells/well with no direct contact with ATII cells.

extract_protocol: Total RNA was extracted from co-cultured human AT II cells and human MSCs using RNA STAT (Tel-Test, Friendswood, TX) per the manufacturer's instructions. All RNA samples had high integrity and purity as assessed by an Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alto, CA).

treatment_protocol: The co-cultured cells were injured with a mixture of different cytokines referred to as cytomix (IL-1β, TNFα, and IFNγ, 50 ng/ml each).

value: bone marrow

tag: condition

value: stimulated eith cytomix


title: ISOPROPAMIDE.IODIDE_OCI-Ly3_24_TH001_NG_101128_02_D04

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_D04

value: 24 hrs


title: TRIMETHADIONE_OCI-Ly3_24_TH001_NG_101128_02_D09

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_D09

value: TRIMETHADIONE


title: MSC transwell rep5

description: gene expression of MSC treatment

value: co-cultured with MSC


title: RIBAVIRIN_OCI-Ly3_24_TH001_NG_101128_02_H08

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_H08

value: RIBAVIRIN


title: MSC cyto rep1

description: gene expression of MSC stimulated


title: NITROFURAZONE_OCI-Ly3_24_TH001_NG_101128_02_E04

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_E04

value: NITROFURAZONE


title: SULINDAC_OCI-Ly3_24_TH001_NG_101128_02_D05

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_D05

value: SULINDAC


title: RIFABUTIN_OCI-Ly3_24_TH001_NG_101128_02_C12

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_C12

value: RIFABUTIN


title: TOPOTECAN.HYDROCHLORIDE_OCI-Ly3_24_TH001_NG_101128_02_D08

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_D08


title: DEFEROXAMINE.MESYLATE_OCI-Ly3_24_TH001_NG_101128_02_D03

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_D03


title: AZATHIOPRINE_OCI-Ly3_24_TH001_NG_101128_02_D02

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_D02

value: AZATHIOPRINE


title: THIOTHIXENE_OCI-Ly3_24_TH001_NG_101128_02_E05

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_E05

value: THIOTHIXENE


title: CLOZAPINE_OCI-Ly3_24_TH001_NG_101128_02_D06

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_D06

value: CLOZAPINE


title: Itraconazole_OCI-Ly3_24_TH001_NG_101128_02_D11

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_D11

value: Itraconazole


title: MELPHALAN_OCI-Ly3_24_TH001_NG_101128_02_D01

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_D01

value: MELPHALAN


title: MSC cyto rep3

description: gene expression of MSC stimulated


title: MSC ctrl rep2

description: gene expression of MSC baseline

value: baseline


title: MSC ctrl rep3

description: gene expression of MSC baseline


title: MSC ctrl rep1

description: gene expression of MSC baseline


title: VINCRISTINE.SULFATE_OCI-Ly3_24_TH001_NG_101128_02_D07

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_D07


title: TROGLITAZONE_OCI-Ly3_24_TH001_NG_101128_02_C11

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_C11

value: TROGLITAZONE


title: MSC transwell rep2

description: gene expression of MSC treatment


title: MSC transwell rep4

description: gene expression of MSC treatment


title: FULVESTRANT_OCI-Ly3_24_TH001_NG_101128_02_C10

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_C10

value: FULVESTRANT


title: ACETOHEXAMIDE_OCI-Ly3_24_TH001_NG_101128_02_C09

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_C09

value: ACETOHEXAMIDE


title: MSC transwell rep3

description: gene expression of MSC treatment

value: bone marrow


title: alveolar type2 cyto MSC rep5

description: gene expression data for alveolar type2 treatment

source_name: alveolar type2

value: lung


title: alveolar type2 cyto MSC rep1


title: MSC transwell rep1

description: gene expression of MSC treatment


title: DIGITOXIN_OCI-Ly3_24_TH001_NG_101128_02_C08

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_C08

value: DIGITOXIN

value: 24 hrs


title: alveolar type2 cyto MSC rep3

value: co-cultured with MSC


title: DACTINOMYCIN_OCI-Ly3_24_TH001_NG_101128_02_C07

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_C07

value: DACTINOMYCIN


title: alveolar type2 cyto rep2

description: gene expression data for alveolar type2 stimulated

value: stimulated eith cytomix


title: alveolar type2 cyto MSC rep2


title: ACRISORCIN_OCI-Ly3_24_TH001_NG_101128_02_C02

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_C02

value: ACRISORCIN


title: alveolar type2 cyto rep3


title: alveolar type2 cyto MSC rep4


title: RISPERIDONE_OCI-Ly3_24_TH001_NG_101128_02_B12

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_B12

value: RISPERIDONE


title: alveolar type2 cyto rep1


title: FLURBIPROFEN_OCI-Ly3_24_TH001_NG_101128_02_C04

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_C04

value: FLURBIPROFEN


title: alveolar type2 ctrl rep3

description: gene expression data for alveolar type2 baseline


title: alveolar type2 ctrl rep2


title: MEBENDAZOLE_OCI-Ly3_24_TH001_NG_101128_02_C01

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_C01

value: MEBENDAZOLE


title: PICROPODOPHYLLIN_OCI-Ly3_24_TH001_NG_101128_02_B10

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_B10

value: PICROPODOPHYLLIN


title: SULFACETAMIDE_OCI-Ly3_24_TH001_NG_101128_02_C05

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_C05

value: SULFACETAMIDE


title: ESTRADIOL_OCI-Ly3_24_TH001_NG_101128_02_C03

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_C03

value: ESTRADIOL


title: Mometasone.furoate_OCI-Ly3_24_TH001_NG_101128_02_B11

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_B11


title: alveolar type2 ctrl rep5

value: baseline


title: VINBLASTINE.SULFATE_OCI-Ly3_24_TH001_NG_101128_02_B08

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_B08


title: TIOCONAZOLE_OCI-Ly3_24_TH001_NG_101128_02_B09

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_B09

value: TIOCONAZOLE


title: SULFASALAZINE_OCI-Ly3_24_TH001_NG_101128_02_B06

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_B06

value: SULFASALAZINE


title: TRIFLUPROMAZINE.HYDROCHLORIDE_OCI-Ly3_24_TH001_NG_101128_02_B07

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_B07


title: TRIFLUOPERAZINE.HYDROCHLORIDE_OCI-Ly3_24_TH001_NG_101128_02_C06

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_C06


title: alveolar type2 cyto rep4


title: alveolar type2 ctrl rep4


title: THIOGUANINE_OCI-Ly3_24_TH001_NG_101128_02_B05

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_B05

value: THIOGUANINE


title: alveolar type2 ctrl rep1

value: lung


title: E.coli gene expression data in complementation of NC domain of trigger factor

city: Beijing

first: Dongjie

last: Fan

address: Changbai Road NO 155,

country: China

institute: National institute for communicable disease control and prevention,Chinese center for disease control and prevention

description: NC

hyb_protocol: The 9300 E.coli genome oligo-arrays were manufactured by CapitalBio Corp.(Beijing,China) using the 5'-amino-modified operon 70-mer probe library(Operon, Huntsville,AL,USA).In addition to E.coli 4 house-keeping genes as internal controls,8 intergenic sequences from yeast were used as external controls. All nucleotides were dissolved in DNA spotting solution at 0.02 mM and printed on aminosilane-coated glass slides using SmartArray-136TM spotter(CapitalBio).After printing,the slides were baked for 1 h at 80 degrees and stored dry at room temperature unit use. Prior hybridization, the slides were rehydrated over 65 degrees water for 10s and UV cross-linked. The non-immoblized oligonucleotides were washed off with 0.5% SDS solution for 10 min at 42 degrees, and SDS was removed by dipping the slides in anhydrous ethanol for 30 s. Labeled control and experimental samples were quantitatively adjusted based on the efficiency of Cy-dye incorporation and mixed into hybridization solution [3×saline-sodium citrate(SSC),0.2% SDS,25% formamide and 5×Denhart's]. Microarrays were hybridized at 42 degrees overnight and washed with two consecutive washing solution (0.2% SDS,2×SSC at 42 degrees and 0.2% SSC) for 5 min at room temperature.

scan_protocol: After hybridization, slides were scanned with a confocal scanner LuxScanTM 10KA.

data_processing: The signal/noise ratio for each array was calculated, for each spot and each channel, as (foreground intensity minus background intensity)/(standard deviation of the background). The raw data were normalized  using a space and intensity-dependant LOWESS program. Faint spots were removed from the data if the intensities were lower than the average intensity plus 2 standard deviations of the negative controls. The significant genes differentiating wild-type and deleting dnaK were selected based on q<0.05 and greater than twofold as criteria.

organism: Escherichia coli

source_name: BW25113_complementing NC domain of Trigger Factor_37 °C

label_protocol: Total RNA was reverse transcripted into cDNA using random primers.The cDNA were purified by PCR NucleoSpin Extract II kit(MN)and vacuum evaporated. The fluorescence labeling reactions contained Klenow enzyme,dNTP,Cy5-dCTP and Cy3-dCTP (GE Healthcare). The reaction was carried out at 37 °C for 90 min and stopped by addition of 25mM EDTA and 0.25% sodium dodecyl sulfate. Labeled DNA targets were purified by PCR NucleoSpin Extract II Kit(MN).

extract_protocol: Total RNA was isolated from strains using NucleoSpin RNAII kit (Macherey-Nagel Corporation) following the instruction. RNA samples were examined in a 1.5% denaturing agarose gel, quantitated by absorbance at 260 nm and stored until further use for microarray.

tag: strain background

source_name: BW25113_wild type_37 °C

value: wild type


title: E.coli gene expression data in deletion of chaperone Trigger Factor

source_name: BW25113_deleting Trigger Factor_37 °C

value: deletion of chaperone Trigger Factor


title: ROSIGLITAZONE_OCI-Ly3_24_TH001_NG_101128_02_B02

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_B02

value: ROSIGLITAZONE

value: 24 hrs


title: Lung post-infection 7 day

city: Seoul

first: Hyun Jik

last: Kim

address: 101 Daehak-ro, Jongno-gu

department: Department of otorhinolaryngology

country: South Korea

institute: Seoul National University

description: PI 7 day

hyb_protocol: Following fragmentation, 0.75 ug of cRNA were hybridized to the Illumina Expression Beadchip according to the protocols provided by the manufacturer

scan_protocol: Arrays were scanned using the Illumina Bead Array Reader Confocal Scanner

data_processing: Array data export processing and analysis was performed using Illumina GenomeStudio v2011.1 (Gene Expression Module v1.9.0)

source_name: lung

label_protocol: Biotinylated cRNA were prepared from 0.55 ug total RNA using the Illumina TotalPrep RNA Amplification Kit (Ambion, Austin,TX)

growth_protocol: Male C57BL/6J mice aged 7 weeks (19–23 g) were used as wild-type (WT), and IAV (WS/33, H1N1; 213 pfu in 30 μl PBS) was inoculated into WT mice by intranasal delivery.

extract_protocol: Total RNA was isolated from lung tissue of mice which were infected with WS/33 (H1N1) at day two using TRIzol. cDNA was synthesized from 3 μg of RNA with random hexamer primers using Moloney murine leukemia virus reverse transcriptase.

treatment_protocol: Mouse lung tissue which were also harvested for microarray and total RNA was isolated from homogenized mouse lung tissue infected with WS/33 at 7,days using TRIzol.

tag: gender

value: male

tag: age

value: 7 weeks

tag: infection

value: IAV

value: post-infection day 7

value: lung parenchyme


title: E.coli gene expression data in complementation of NM domain of trigger factor

description: NM

source_name: BW25113_complementing NM domain of Trigger Factor_37 °C


title: FENOFIBRATE_OCI-Ly3_24_TH001_NG_101128_02_B01

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_B01

value: FENOFIBRATE


title: ERGOCALCIFEROL_OCI-Ly3_24_TH001_NG_101128_02_B03

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_B03

value: ERGOCALCIFEROL


title: MITOXANTHRONE.HYDROCHLORIDE_OCI-Ly3_24_TH001_NG_101128_02_A08

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_A08


title: Lung post-infection 0 day

description: PI 0 day

value: post-infection day 0


title: Primary tumor breast - BCPT0635

city: Stockholm

first: Alexandra

last: Jauhiainen

address: PO Box 281

department: Medical Epidemiology and Biostatistics

country: Sweden

institute: Karolinska Institutet

description: Some arrays correspond to multiple study subjects, which is indicated by the setnr/case-control status

hyb_protocol: Fragmented and biotinylated cRNA (10 μg) was hybridized at 45C for 16 h to a high density oligonucleotide custom made Affymetrix array chip (Human Cancer G110 Array). The arrays were then washed, stained with streptavidin-phycoerythrin (SAPE, final concentration of 10 μg/ml).

scan_protocol: The arrays were scanned according to the manufacturer’s instructions (Affymetrix Genechip® Technical Manual, 2001). The scanned images were inspected for the presence of obvious defects (artifacts or scratches) on the array. In case of visible microarray artifacts, the sample was rehybridized and rescanned on new chips using the same fragmented probe.

data_processing: The microarray analysis was done in the open source software R using the aroma.affymetrix package. Each array was individually background corrected and normalized using robust multichip averaging (RMA). The arrays were then quantile normalized for comparability. Only perfect match (PM) probes were used in the normalization steps. The signals from multiple PM probes targeting the same transcript were summarized using a probe level model adjusting for chip effects. A variance filter was employed and probes with inter-quartile-range less than 0.5 were excluded, resulting in 28449 retained probes.

source_name: Primary tumor breast

label_protocol: Preparation of in vitro transcription (IVT) products and oligonucleotide array hybridization and scanning were performed according to the Affymetrix protocol (Santa Clara, CA, USA). In brief, the amount of starting total RNA for each probe preparation varied between 2 and 5 μg. IVT reactions were performed in batches to generate biotinylated cRNA targets, which were subsequently chemically fragmented at 95C for 35 min.

extract_protocol: Extraction of total RNA from frozen tumors was carried out using the Qiagen RNeasy Mini Kit (Qiagen, Germany). The integrity of the RNA extracts was tested on an Agilent 2100 Bioanalyzer (Agilent Technologies, Rockville, MD), measuring the 28S: 18S ribosomal RNA ratio. RNA extracts of high quality were stored at -70C until microarray analyses.

treatment_protocol: The fresh frozen tumor samples were collected from liquid nitrogen and cryosectioning was performed on a Cryo-Star HM 560 M. Five μm sections were cut from the surface of the same tumor sample that was used for isolation of RNA and DNA. The section was counterstained with hematoxylin and eosin and dehydrated through graded concentrations of ethanol to xylene before mounting. The percentage of tumor cells, as well as the percentage of epithelial cancer cells in relation to stroma, was quantified in the frozen tumor sections by a breast cancer pathologist.

tag: sample group

value: validation

tag: setnr

tag: case-control status

value: Primary tumor breast


title: MICONAZOLE.NITRATE_OCI-Ly3_24_TH001_NG_101128_02_B04

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_B04

tag: cell line


title: Primary tumor breast - BCPT0043

tag: tissue


title: DMSO_OCI-Ly3_24_TH001_NG_101128_02_A12

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_A12

value: DMSO


title: CHLOROXINE_OCI-Ly3_24_TH001_NG_101128_02_A07

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_A07

value: CHLOROXINE


title: Primary tumor breast - BCPT0327

value: discovery


title: E.coli gene expression data in complementation of MC domain of trigger factor

description: MC

source_name: BW25113_complementing MC domain of Trigger Factor_37 °C

tag: genotype/variation

value: wild type


title: Primary tumor breast - BCPT0417


title: TUBOCURARINE.CHLORIDE_OCI-Ly3_24_TH001_NG_101128_02_A10

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_A10


title: Metixene.hydrochloride_OCI-Ly3_24_TH001_NG_101128_02_A11

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_A11


title: NISOLDIPINE_OCI-Ly3_24_TH001_NG_101128_02_A09

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_A09

value: NISOLDIPINE


title: SULCONAZOLE.NITRATE_OCI-Ly3_24_TH001_NG_101128_02_A02

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_A02


title: Primary tumor breast - BCPT0677


title: PINDOLOL_OCI-Ly3_24_TH001_NG_101128_02_A06

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_A06

value: PINDOLOL


title: SULFINPYRAZONE_OCI-Ly3_24_TH001_NG_101128_02_A05

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_A05

value: SULFINPYRAZONE

value: 24 hrs


title: Primary tumor breast - BCPT0373


title: Primary tumor breast - BCPT0080


title: PENTOXIFYLLINE_OCI-Ly3_6_TH001_NG_101020_02_H09

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_H09

value: PENTOXIFYLLINE

value: 6 hrs


title: ALPROSTADIL_OCI-Ly3_6_TH001_NG_101020_02_H11

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_H11

value: ALPROSTADIL


title: HEXACHLOROPHENE_OCI-Ly3_24_TH001_NG_101128_02_A04

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_A04

value: HEXACHLOROPHENE


title: Primary tumor breast - BCPT0358


title: Primary tumor breast - BCPT0896


title: CLOMIPHENE.CITRATE_OCI-Ly3_24_TH001_NG_101128_02_A03

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_A03


title: Primary tumor breast - BCPT0694


title: FELODIPINE_OCI-Ly3_6_TH001_NG_101020_02_H10

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_H10

value: FELODIPINE


title: Primary tumor breast - BCPT0088


title: Primary tumor breast - BCPT0993


title: Primary tumor breast - BCPT0195


title: DAPSONE_OCI-Ly3_6_TH001_NG_101020_02_H02

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_H02

value: DAPSONE


title: INDAPAMIDE_OCI-Ly3_6_TH001_NG_101020_02_H04

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_H04

value: INDAPAMIDE


title: PROMAZINE.HYDROCHLORIDE_OCI-Ly3_6_TH001_NG_101020_02_H05

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_H05


title: Primary tumor breast - BCPT0920

description: Some arrays correspond to multiple study subjects, which is indicated by the setnr/case-control status


title: RIBAVIRIN_OCI-Ly3_6_TH001_NG_101020_02_H08

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_H08

value: RIBAVIRIN


title: DMSO_OCI-Ly3_6_TH001_NG_101020_02_H12

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_H12


title: Primary tumor breast - BCPT0714

value: Primary tumor breast


title: Primary tumor breast - BCPT0818


title: Primary tumor breast - BCPT0797


title: REF_HeLa_NA_TH001_NG_101128_02_A01

description:
tumor cell line
Therasis_Plate9_TH001_NG_20101128_02_A01

source_name: HeLa

value: REF

value: HeLa


title: TINIDAZOLE_OCI-Ly3_6_TH001_NG_101020_02_H06

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_H06

value: TINIDAZOLE


title: Primary tumor breast - BCPT0588

value: discovery


title: Primary tumor breast - BCPT0627


title: Primary tumor breast - BCPT0549

value: validation


title: Gemcitabine_OCI-Ly3_6_TH001_NG_101020_02_H07

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_H07

value: Gemcitabine


title: GEMFIBROZIL_OCI-Ly3_6_TH001_NG_101020_02_H03

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_H03

value: GEMFIBROZIL


title: Toremifene_OCI-Ly3_6_TH001_NG_101020_02_G11

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_G11

value: Toremifene


title: Primary tumor breast - BCPT0240


title: DMSO_OCI-Ly3_6_TH001_NG_101020_02_H01

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_H01

value: DMSO


title: Primary tumor breast - BCPT0224


title: VALPROIC.ACID_OCI-Ly3_6_TH001_NG_101020_02_G12

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_G12

value: 6 hrs


title: DIMERCAPROL_OCI-Ly3_6_TH001_NG_101020_02_G09

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_G09

value: DIMERCAPROL


title: Primary tumor breast - BCPT0214


title: Primary tumor breast - BCPT0479


title: ALTRETAMINE_OCI-Ly3_6_TH001_NG_101020_02_G06

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_G06

value: ALTRETAMINE


title: Butoconazole.nitrate_OCI-Ly3_6_TH001_NG_101020_02_G10

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_G10


title: Primary tumor breast - BCPT0493


title: HYDROCHLOROTHIAZIDE_OCI-Ly3_6_TH001_NG_101020_02_G04

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_G04

value: HYDROCHLOROTHIAZIDE


title: Primary tumor breast - BCPT0870


title: CYTARABINE_OCI-Ly3_6_TH001_NG_101020_02_G08

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_G08

value: CYTARABINE


title: TRANEXAMIC.ACID_OCI-Ly3_6_TH001_NG_101020_02_G01

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_G01


title: TAMOXIFEN.CITRATE_OCI-Ly3_6_TH001_NG_101020_02_G05

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_G05


title: Primary tumor breast - BCPT0618

description: Some arrays correspond to multiple study subjects, which is indicated by the setnr/case-control status


title: GRAMICIDIN_OCI-Ly3_6_TH001_NG_101020_02_G07

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_G07

value: GRAMICIDIN


title: CLEMASTINE_OCI-Ly3_6_TH001_NG_101020_02_G02

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_G02

value: CLEMASTINE


title: Primary tumor breast - BCPT0238

value: Primary tumor breast


title: Primary tumor breast - BCPT0215


title: Primary tumor breast - BCPT0163


title: INDOMETHACIN_OCI-Ly3_6_TH001_NG_101020_02_G03

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_G03

value: INDOMETHACIN


title: Primary tumor breast - BCPT0812


title: Primary tumor breast - BCPT0827


title: Cladribine_OCI-Ly3_6_TH001_NG_101020_02_F12

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_F12

value: Cladribine


title: Primary tumor breast - BCPT0668


title: NIZATIDINE_OCI-Ly3_6_TH001_NG_101020_02_F11

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_F11

value: NIZATIDINE


title: Primary tumor breast - BCPT0585

value: discovery


title: Auranofin_OCI-Ly3_6_TH001_NG_101020_02_F08

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_F08

value: Auranofin


title: Primary tumor breast - BCPT0645


title: Primary tumor breast - BCPT0723


title: ENOXACIN_OCI-Ly3_6_TH001_NG_101020_02_F06

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_F06

value: ENOXACIN


title: Primary tumor breast - BCPT0340


title: Primary tumor breast - BCPT0003

value: validation


title: ETHOPROPAZINE.HYDROCHLORIDE_OCI-Ly3_6_TH001_NG_101020_02_F04

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_F04


title: PYRITHIONE.ZINC_OCI-Ly3_6_TH001_NG_101020_02_F07

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_F07


title: AMIODARONE.HYDROCHLORIDE_OCI-Ly3_6_TH001_NG_101020_02_F09

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_F09


title: SULFAMERAZINE_OCI-Ly3_6_TH001_NG_101020_02_F05

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_F05

value: SULFAMERAZINE


title: CHLORMEZANONE_OCI-Ly3_6_TH001_NG_101020_02_E10

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_E10

value: CHLORMEZANONE


title: Irinotecan.Hydrochloride_OCI-Ly3_6_TH001_NG_101020_02_E11

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_E11

value: 6 hrs


title: Primary tumor breast - BCPT0940


title: Primary tumor breast - BCPT0104


title: Primary tumor breast - BCPT0311


title: FOLIC.ACID_OCI-Ly3_6_TH001_NG_101020_02_F01

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_F01


title: Primary tumor breast - BCPT0509


title: GALLAMINE.TRIETHIODIDE_OCI-Ly3_6_TH001_NG_101020_02_F03

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_F03


title: Primary tumor breast - BCPT0571


title: Primary tumor breast - BCPT0855


title: TENIPOSIDE_OCI-Ly3_6_TH001_NG_101020_02_E08

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_E08

value: TENIPOSIDE


title: APOMORPHINE.HYDROCHLORIDE_OCI-Ly3_6_TH001_NG_101020_02_F02

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_F02


title: Primary tumor breast - BCPT0413

description: Some arrays correspond to multiple study subjects, which is indicated by the setnr/case-control status


title: CEFIXIME_OCI-Ly3_6_TH001_NG_101020_02_F10

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_F10

value: CEFIXIME


title: GLIPIZIDE_OCI-Ly3_6_TH001_NG_101020_02_E09

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_E09

value: GLIPIZIDE


title: IMATINIB_OCI-Ly3_6_TH001_NG_101020_02_E12

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_E12

value: IMATINIB


title: Primary tumor breast - BCPT0947


title: Docetaxel_OCI-Ly3_6_TH001_NG_101020_02_E07

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_E07

value: Docetaxel


title: Primary tumor breast - BCPT0210


title: Primary tumor breast - BCPT0564


title: Primary tumor breast - BCPT0375


title: THIOTHIXENE_OCI-Ly3_6_TH001_NG_101020_02_E05

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_E05

value: THIOTHIXENE


title: Primary tumor breast - BCPT0217

value: Primary tumor breast


title: Primary tumor breast - BCPT0859


title: ETOPOSIDE_OCI-Ly3_6_TH001_NG_101020_02_E06

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_E06

value: ETOPOSIDE


title: Primary tumor breast - BCPT0641


title: NITROFURAZONE_OCI-Ly3_6_TH001_NG_101020_02_E04

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_E04

value: NITROFURAZONE


title: Primary tumor breast - BCPT0074


title: Primary tumor breast - BCPT0188


title: Primary tumor breast - BCPT0052


title: Itraconazole_OCI-Ly3_6_TH001_NG_101020_02_D11

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_D11

value: Itraconazole


title: SULINDAC_OCI-Ly3_6_TH001_NG_101020_02_D05

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_D05

value: SULINDAC


title: VORINOSTAT_OCI-Ly3_6_TH001_NG_101020_02_D12

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_D12

value: VORINOSTAT


title: VINCRISTINE.SULFATE_OCI-Ly3_6_TH001_NG_101020_02_D07

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_D07


title: Primary tumor breast - BCPT0523

value: discovery


title: MITOMYCIN.C_OCI-Ly3_6_TH001_NG_101020_02_E02

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_E02


title: Primary tumor breast - BCPT0530


title: ECONAZOLE.NITRATE_OCI-Ly3_6_TH001_NG_101020_02_E01

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_E01


title: BRINZOLAMIDE_OCI-Ly3_6_TH001_NG_101020_02_D10

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_D10

value: BRINZOLAMIDE


title: TOPOTECAN.HYDROCHLORIDE_OCI-Ly3_6_TH001_NG_101020_02_D08

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_D08


title: Primary tumor breast - BCPT0851

value: validation


title: Primary tumor breast - BCPT0890


title: CLOZAPINE_OCI-Ly3_6_TH001_NG_101020_02_D06

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_D06

value: CLOZAPINE


title: ISOPROPAMIDE.IODIDE_OCI-Ly3_6_TH001_NG_101020_02_D04

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_D04

value: 6 hrs


title: TRIMETHADIONE_OCI-Ly3_6_TH001_NG_101020_02_D09

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_D09

value: TRIMETHADIONE


title: DEFEROXAMINE.MESYLATE_OCI-Ly3_6_TH001_NG_101020_02_D03

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_D03


title: Primary tumor breast - BCPT0663

description: Some arrays correspond to multiple study subjects, which is indicated by the setnr/case-control status


title: Primary tumor breast - BCPT0071


title: Primary tumor breast - BCPT0343


title: MELPHALAN_OCI-Ly3_6_TH001_NG_101020_02_D01

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_D01

value: MELPHALAN


title: Primary tumor breast - BCPT0647


title: Primary tumor breast - BCPT0702


title: AZATHIOPRINE_OCI-Ly3_6_TH001_NG_101020_02_D02

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_D02

value: AZATHIOPRINE


title: ACETOHEXAMIDE_OCI-Ly3_6_TH001_NG_101020_02_C09

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_C09

value: ACETOHEXAMIDE


title: Primary tumor breast - BCPT0266


title: Primary tumor breast - BCPT0485


title: DIGITOXIN_OCI-Ly3_6_TH001_NG_101020_02_C08

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_C08

value: DIGITOXIN


title: RIFABUTIN_OCI-Ly3_6_TH001_NG_101020_02_C12

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_C12

value: RIFABUTIN


title: SULFACETAMIDE_OCI-Ly3_6_TH001_NG_101020_02_C05

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_C05

value: SULFACETAMIDE


title: Primary tumor breast - BCPT0652

value: Primary tumor breast


title: TROGLITAZONE_OCI-Ly3_6_TH001_NG_101020_02_C11

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_C11

value: TROGLITAZONE


title: ESTRADIOL_OCI-Ly3_6_TH001_NG_101020_02_C03

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_C03

value: ESTRADIOL


title: FLURBIPROFEN_OCI-Ly3_6_TH001_NG_101020_02_C04

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_C04

value: FLURBIPROFEN


title: MEBENDAZOLE_OCI-Ly3_6_TH001_NG_101020_02_C01

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_C01

value: MEBENDAZOLE


title: FULVESTRANT_OCI-Ly3_6_TH001_NG_101020_02_C10

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_C10

value: FULVESTRANT


title: Primary tumor breast - BCPT0799

value: discovery


title: Primary tumor breast - BCPT0207


title: Primary tumor breast - BCPT0086


title: DACTINOMYCIN_OCI-Ly3_6_TH001_NG_101020_02_C07

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_C07

value: DACTINOMYCIN


title: TRIFLUOPERAZINE.HYDROCHLORIDE_OCI-Ly3_6_TH001_NG_101020_02_C06

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_C06


title: DYCLONINE.HYDROCHLORIDE_OCI-Ly3_6_TH001_NG_101020_02_E03

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_E03


title: Mometasone.furoate_OCI-Ly3_6_TH001_NG_101020_02_B11

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_B11


title: ACRISORCIN_OCI-Ly3_6_TH001_NG_101020_02_C02

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_C02

value: ACRISORCIN


title: RISPERIDONE_OCI-Ly3_6_TH001_NG_101020_02_B12

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_B12

value: RISPERIDONE

value: 6 hrs


title: PICROPODOPHYLLIN_OCI-Ly3_6_TH001_NG_101020_02_B10

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_B10

value: PICROPODOPHYLLIN


title: Primary tumor breast - BCPT0932

description: Some arrays correspond to multiple study subjects, which is indicated by the setnr/case-control status

value: validation


title: Primary tumor breast - BCPT0072


title: Primary tumor breast - BCPT0051


title: Primary tumor breast - BCPT0179


title: Primary tumor breast - BCPT0213


title: Primary tumor breast - BCPT0140


title: Primary tumor breast - BCPT0531


title: Primary tumor breast - BCPT0143


title: VINBLASTINE.SULFATE_OCI-Ly3_6_TH001_NG_101020_02_B08

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_B08


title: Primary tumor breast - BCPT0440


title: SULFASALAZINE_OCI-Ly3_6_TH001_NG_101020_02_B06

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_B06

value: SULFASALAZINE


title: TIOCONAZOLE_OCI-Ly3_6_TH001_NG_101020_02_B09

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_B09

value: TIOCONAZOLE


title: MICONAZOLE.NITRATE_OCI-Ly3_6_TH001_NG_101020_02_B04

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_B04


title: ROSIGLITAZONE_OCI-Ly3_6_TH001_NG_101020_02_B02

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_B02

value: ROSIGLITAZONE


title: TRIFLUPROMAZINE.HYDROCHLORIDE_OCI-Ly3_6_TH001_NG_101020_02_B07

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_B07


title: Primary tumor breast - BCPT0318


title: Primary tumor breast - BCPT0603


title: THIOGUANINE_OCI-Ly3_6_TH001_NG_101020_02_B05

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_B05

value: THIOGUANINE


title: ERGOCALCIFEROL_OCI-Ly3_6_TH001_NG_101020_02_B03

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_B03

value: ERGOCALCIFEROL


title: Primary tumor breast - BCPT0554

value: Primary tumor breast


title: FENOFIBRATE_OCI-Ly3_6_TH001_NG_101020_02_B01

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_B01

value: FENOFIBRATE


title: NISOLDIPINE_OCI-Ly3_6_TH001_NG_101020_02_A09

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_A09

value: NISOLDIPINE


title: Primary tumor breast - BCPT0155


title: Metixene.hydrochloride_OCI-Ly3_6_TH001_NG_101020_02_A11

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_A11


title: Primary tumor breast - BCPT0662


title: MITOXANTHRONE.HYDROCHLORIDE_OCI-Ly3_6_TH001_NG_101020_02_A08

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_A08


title: TUBOCURARINE.CHLORIDE_OCI-Ly3_6_TH001_NG_101020_02_A10

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_A10


title: DMSO_OCI-Ly3_6_TH001_NG_101020_02_A12

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_A12

value: DMSO


title: DMSO_OCI-Ly3_6_TH001_NG_101020_02_A01

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_A01


title: CLOMIPHENE.CITRATE_OCI-Ly3_6_TH001_NG_101020_02_A03

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_A03


title: Primary tumor breast - BCPT0533

description: Some arrays correspond to multiple study subjects, which is indicated by the setnr/case-control status


title: Primary tumor breast - BCPT0453


title: DMSO_U2932_24_TH001_NG_101118_08_H12

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_H12

value: 24 hrs


title: SULFINPYRAZONE_OCI-Ly3_6_TH001_NG_101020_02_A05

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_A05

value: SULFINPYRAZONE


title: PINDOLOL_OCI-Ly3_6_TH001_NG_101020_02_A06

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_A06

value: PINDOLOL


title: Primary tumor breast - BCPT0658

value: discovery


title: Primary tumor breast - BCPT0089


title: Primary tumor breast - BCPT0005


title: Primary tumor breast - BCPT0268


title: Primary tumor breast - BCPT0543


title: Primary tumor breast - BCPT0864


title: PENTOXIFYLLINE_U2932_24_TH001_NG_101118_08_H09

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_H09

value: PENTOXIFYLLINE


title: HEXACHLOROPHENE_OCI-Ly3_6_TH001_NG_101020_02_A04

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_A04

value: HEXACHLOROPHENE

value: 6 hrs


title: CHLOROXINE_OCI-Ly3_6_TH001_NG_101020_02_A07

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_A07

value: CHLOROXINE


title: SULCONAZOLE.NITRATE_OCI-Ly3_6_TH001_NG_101020_02_A02

description:
tumor cell line
Therasis_Plate8_TH001_NG_20101020_02_A02


title: FELODIPINE_U2932_24_TH001_NG_101118_08_H10

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_H10

value: FELODIPINE


title: Primary tumor breast - BCPT0349


title: Primary tumor breast - BCPT0552


title: Primary tumor breast - BCPT0783

value: validation


title: RIBAVIRIN_U2932_24_TH001_NG_101118_08_H08

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_H08

value: RIBAVIRIN


title: GEMFIBROZIL_U2932_24_TH001_NG_101118_08_H03

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_H03

value: GEMFIBROZIL


title: Gemcitabine_U2932_24_TH001_NG_101118_08_H07

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_H07

value: Gemcitabine


title: PROMAZINE.HYDROCHLORIDE_U2932_24_TH001_NG_101118_08_H05

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_H05


title: ALPROSTADIL_U2932_24_TH001_NG_101118_08_H11

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_H11

value: ALPROSTADIL


title: DAPSONE_U2932_24_TH001_NG_101118_08_H02

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_H02

value: DAPSONE


title: INDAPAMIDE_U2932_24_TH001_NG_101118_08_H04

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_H04

value: INDAPAMIDE


title: TINIDAZOLE_U2932_24_TH001_NG_101118_08_H06

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_H06

value: TINIDAZOLE


title: Primary tumor breast - BCPT0016

description: Some arrays correspond to multiple study subjects, which is indicated by the setnr/case-control status

value: Primary tumor breast


title: Primary tumor breast - BCPT0384


title: DMSO_U2932_24_TH001_NG_101118_08_H01

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_H01

value: DMSO

value: 24 hrs


title: Primary tumor breast - BCPT0637


title: Primary tumor breast - BCPT0872

value: discovery


title: Primary tumor breast - BCPT0942


title: Toremifene_U2932_24_TH001_NG_101118_08_G11

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_G11

value: Toremifene


title: Primary tumor breast - BCPT0226


title: Primary tumor breast - BCPT0838


title: TAMOXIFEN.CITRATE_U2932_24_TH001_NG_101118_08_G05

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_G05


title: INDOMETHACIN_U2932_24_TH001_NG_101118_08_G03

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_G03

value: INDOMETHACIN


title: DIMERCAPROL_U2932_24_TH001_NG_101118_08_G09

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_G09

value: DIMERCAPROL


title: HYDROCHLOROTHIAZIDE_U2932_24_TH001_NG_101118_08_G04

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_G04

value: HYDROCHLOROTHIAZIDE


title: GRAMICIDIN_U2932_24_TH001_NG_101118_08_G07

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_G07

value: GRAMICIDIN


title: AMIODARONE.HYDROCHLORIDE_U2932_24_TH001_NG_101118_08_F09

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_F09


title: VALPROIC.ACID_U2932_24_TH001_NG_101118_08_G12

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_G12


title: Primary tumor breast - BCPT0081


title: Primary tumor breast - BCPT0400


title: Primary tumor breast - BCPT0219

value: validation


title: CYTARABINE_U2932_24_TH001_NG_101118_08_G08

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_G08

value: CYTARABINE


title: NIZATIDINE_U2932_24_TH001_NG_101118_08_F11

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_F11

value: NIZATIDINE


title: Primary tumor breast - BCPT0750


title: ALTRETAMINE_U2932_24_TH001_NG_101118_08_G06

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_G06

value: ALTRETAMINE


title: Primary tumor breast - BCPT0200


title: Primary tumor breast - BCPT0425


title: Primary tumor breast - BCPT0438


title: CLEMASTINE_U2932_24_TH001_NG_101118_08_G02

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_G02

value: CLEMASTINE


title: Butoconazole.nitrate_U2932_24_TH001_NG_101118_08_G10

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_G10


title: Cladribine_U2932_24_TH001_NG_101118_08_F12

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_F12

value: Cladribine


title: CEFIXIME_U2932_24_TH001_NG_101118_08_F10

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_F10

value: CEFIXIME


title: TRANEXAMIC.ACID_U2932_24_TH001_NG_101118_08_G01

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_G01


title: Primary tumor breast - BCPT0387

description: Some arrays correspond to multiple study subjects, which is indicated by the setnr/case-control status


title: Auranofin_U2932_24_TH001_NG_101118_08_F08

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_F08

value: Auranofin


title: Primary tumor breast - BCPT0480

value: Primary tumor breast


title: Primary tumor breast - BCPT0795


title: Primary tumor breast - BCPT0406


title: Primary tumor breast - BCPT0262


title: Primary tumor breast - BCPT0174


title: Primary tumor breast - BCPT0900


title: Primary tumor breast - BCPT0292


title: FOLIC.ACID_U2932_24_TH001_NG_101118_08_F01

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_F01


title: Irinotecan.Hydrochloride_U2932_24_TH001_NG_101118_08_E11

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_E11


title: ENOXACIN_U2932_24_TH001_NG_101118_08_F06

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_F06

value: ENOXACIN


title: Primary tumor breast - BCPT0959


title: Primary tumor breast - BCPT0352


title: SULFAMERAZINE_U2932_24_TH001_NG_101118_08_F05

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_F05

value: SULFAMERAZINE

value: 24 hrs


title: PYRITHIONE.ZINC_U2932_24_TH001_NG_101118_08_F07

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_F07


title: GALLAMINE.TRIETHIODIDE_U2932_24_TH001_NG_101118_08_F03

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_F03


title: THIOTHIXENE_U2932_24_TH001_NG_101118_08_E05

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_E05

value: THIOTHIXENE


title: Primary tumor breast - BCPT0419


title: GLIPIZIDE_U2932_24_TH001_NG_101118_08_E09

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_E09

value: GLIPIZIDE


title: IMATINIB_U2932_24_TH001_NG_101118_08_E12

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_E12

value: IMATINIB


title: Primary tumor breast - BCPT0973

value: discovery


title: Primary tumor breast - BCPT0064


title: Docetaxel_U2932_24_TH001_NG_101118_08_E07

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_E07

value: Docetaxel


title: ETHOPROPAZINE.HYDROCHLORIDE_U2932_24_TH001_NG_101118_08_F04

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_F04


title: APOMORPHINE.HYDROCHLORIDE_U2932_24_TH001_NG_101118_08_F02

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_F02


title: CHLORMEZANONE_U2932_24_TH001_NG_101118_08_E10

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_E10

value: CHLORMEZANONE


title: TENIPOSIDE_U2932_24_TH001_NG_101118_08_E08

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_E08

value: TENIPOSIDE


title: Primary tumor breast - BCPT0048

value: validation


title: ETOPOSIDE_U2932_24_TH001_NG_101118_08_E06

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_E06

value: ETOPOSIDE


title: DYCLONINE.HYDROCHLORIDE_U2932_24_TH001_NG_101118_08_E03

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_E03


title: Primary tumor breast - BCPT0202

description: Some arrays correspond to multiple study subjects, which is indicated by the setnr/case-control status


title: Primary tumor breast - BCPT0157


title: Primary tumor breast - BCPT0351


title: Itraconazole_U2932_24_TH001_NG_101118_08_D11

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_D11

value: Itraconazole


title: NITROFURAZONE_U2932_24_TH001_NG_101118_08_E04

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_E04

value: NITROFURAZONE


title: ECONAZOLE.NITRATE_U2932_24_TH001_NG_101118_08_E01

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_E01


title: Primary tumor breast - BCPT0692


title: Primary tumor breast - BCPT0514


title: Primary tumor breast - BCPT0899


title: TRIMETHADIONE_U2932_24_TH001_NG_101118_08_D09

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_D09

value: TRIMETHADIONE


title: Primary tumor breast - BCPT0778


title: Primary tumor breast - BCPT0939


title: Primary tumor breast - BCPT0928


title: DEFEROXAMINE.MESYLATE_U2932_24_TH001_NG_101118_08_D03

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_D03


title: AZATHIOPRINE_U2932_24_TH001_NG_101118_08_D02

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_D02

value: AZATHIOPRINE


title: VORINOSTAT_U2932_24_TH001_NG_101118_08_D12

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_D12

value: VORINOSTAT


title: Primary tumor breast - BCPT0028

value: Primary tumor breast


title: Primary tumor breast - BCPT0648


title: Primary tumor breast - BCPT0958


title: Primary tumor breast - BCPT0312


title: Primary tumor breast - BCPT0625


title: ISOPROPAMIDE.IODIDE_U2932_24_TH001_NG_101118_08_D04

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_D04


title: Primary tumor breast - BCPT0448


title: SULINDAC_U2932_24_TH001_NG_101118_08_D05

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_D05

value: SULINDAC


title: MITOMYCIN.C_U2932_24_TH001_NG_101118_08_E02

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_E02

value: 24 hrs


title: CLOZAPINE_U2932_24_TH001_NG_101118_08_D06

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_D06

value: CLOZAPINE


title: TOPOTECAN.HYDROCHLORIDE_U2932_24_TH001_NG_101118_08_D08

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_D08


title: BRINZOLAMIDE_U2932_24_TH001_NG_101118_08_D10

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_D10

value: BRINZOLAMIDE


title: VINCRISTINE.SULFATE_U2932_24_TH001_NG_101118_08_D07

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_D07


title: Primary tumor breast - BCPT0496


title: Primary tumor breast - BCPT0699


title: FULVESTRANT_U2932_24_TH001_NG_101118_08_C10

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_C10

value: FULVESTRANT


title: RIFABUTIN_U2932_24_TH001_NG_101118_08_C12

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_C12

value: RIFABUTIN


title: MELPHALAN_U2932_24_TH001_NG_101118_08_D01

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_D01

value: MELPHALAN


title: Primary tumor breast - BCPT0124

description: Some arrays correspond to multiple study subjects, which is indicated by the setnr/case-control status


title: TROGLITAZONE_U2932_24_TH001_NG_101118_08_C11

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_C11

value: TROGLITAZONE


title: ACETOHEXAMIDE_U2932_24_TH001_NG_101118_08_C09

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_C09

value: ACETOHEXAMIDE


title: DACTINOMYCIN_U2932_24_TH001_NG_101118_08_C07

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_C07

value: DACTINOMYCIN


title: Primary tumor breast - BCPT0299

value: validation


title: DIGITOXIN_U2932_24_TH001_NG_101118_08_C08

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_C08

value: DIGITOXIN


title: TRIFLUOPERAZINE.HYDROCHLORIDE_U2932_24_TH001_NG_101118_08_C06

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_C06


title: Primary tumor breast - BCPT0444


title: Primary tumor breast - BCPT0033

value: discovery


title: Primary tumor breast - BCPT0796


title: Primary tumor breast - BCPT0974


title: SULFACETAMIDE_U2932_24_TH001_NG_101118_08_C05

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_C05

value: SULFACETAMIDE


title: ESTRADIOL_U2932_24_TH001_NG_101118_08_C03

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_C03

value: ESTRADIOL


title: Primary tumor breast - BCPT0228


title: Primary tumor breast - BCPT0800


title: RISPERIDONE_U2932_24_TH001_NG_101118_08_B12

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_B12

value: RISPERIDONE


title: Primary tumor breast - BCPT0234

value: Primary tumor breast


title: Primary tumor breast - BCPT0158


title: MEBENDAZOLE_U2932_24_TH001_NG_101118_08_C01

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_C01

value: MEBENDAZOLE


title: FLURBIPROFEN_U2932_24_TH001_NG_101118_08_C04

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_C04

value: FLURBIPROFEN

value: 24 hrs


title: Primary tumor breast - BCPT0430


title: Primary tumor breast - BCPT0359


title: Primary tumor breast - BCPT0087


title: ACRISORCIN_U2932_24_TH001_NG_101118_08_C02

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_C02

value: ACRISORCIN


title: PICROPODOPHYLLIN_U2932_24_TH001_NG_101118_08_B10

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_B10

value: PICROPODOPHYLLIN


title: Mometasone.furoate_U2932_24_TH001_NG_101118_08_B11

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_B11


title: VINBLASTINE.SULFATE_U2932_24_TH001_NG_101118_08_B08

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_B08


title: TIOCONAZOLE_U2932_24_TH001_NG_101118_08_B09

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_B09

value: TIOCONAZOLE


title: Primary tumor breast - BCPT0821


title: Primary tumor breast - BCPT0055


title: MICONAZOLE.NITRATE_U2932_24_TH001_NG_101118_08_B04

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_B04


title: THIOGUANINE_U2932_24_TH001_NG_101118_08_B05

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_B05

value: THIOGUANINE


title: Primary tumor breast - BCPT0979

description: Some arrays correspond to multiple study subjects, which is indicated by the setnr/case-control status


title: DMSO_U2932_24_TH001_NG_101118_08_A12

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_A12

value: DMSO


title: SULFASALAZINE_U2932_24_TH001_NG_101118_08_B06

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_B06

value: SULFASALAZINE


title: Primary tumor breast - BCPT0142


title: Primary tumor breast - BCPT0470


title: Primary tumor breast - BCPT0510


title: Primary tumor breast - BCPT0593


title: TUBOCURARINE.CHLORIDE_U2932_24_TH001_NG_101118_08_A10

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_A10


title: ROSIGLITAZONE_U2932_24_TH001_NG_101118_08_B02

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_B02

value: ROSIGLITAZONE


title: Primary tumor breast - BCPT0761

value: validation


title: Primary tumor breast - BCPT0466


title: ERGOCALCIFEROL_U2932_24_TH001_NG_101118_08_B03

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_B03

value: ERGOCALCIFEROL


title: Primary tumor breast - BCPT0297


title: NISOLDIPINE_U2932_24_TH001_NG_101118_08_A09

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_A09

value: NISOLDIPINE


title: TRIFLUPROMAZINE.HYDROCHLORIDE_U2932_24_TH001_NG_101118_08_B07

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_B07


title: SULFINPYRAZONE_U2932_24_TH001_NG_101118_08_A05

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_A05

value: SULFINPYRAZONE


title: Primary tumor breast - BCPT0377

value: discovery


title: Primary tumor breast - BCPT0345


title: Primary tumor breast - BCPT0525


title: Primary tumor breast - BCPT0526


title: HEXACHLOROPHENE_U2932_24_TH001_NG_101118_08_A04

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_A04

value: HEXACHLOROPHENE


title: CHLOROXINE_U2932_24_TH001_NG_101118_08_A07

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_A07

value: CHLOROXINE


title: CLOMIPHENE.CITRATE_U2932_24_TH001_NG_101118_08_A03

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_A03


title: FENOFIBRATE_U2932_24_TH001_NG_101118_08_B01

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_B01

value: FENOFIBRATE


title: Metixene.hydrochloride_U2932_24_TH001_NG_101118_08_A11

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_A11


title: PINDOLOL_U2932_24_TH001_NG_101118_08_A06

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_A06

value: PINDOLOL


title: Primary tumor breast - BCPT0118

value: Primary tumor breast


title: Primary tumor breast - BCPT0605


title: SULCONAZOLE.NITRATE_U2932_24_TH001_NG_101118_08_A02

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_A02

value: 24 hrs


title: REF_HeLa_NA_TH001_NG_101118_08_A01

description:
tumor cell line
Therasis_Plate15_TH001_NG_20101118_08_A01

value: REF

value: HeLa


title: ALPROSTADIL_U2932_12_TH001_NG_101118_07_H11

description:
tumor cell line
Therasis_Plate14_TH001_NG_20101118_07_H11

value: ALPROSTADIL

value: 12 hrs


title: DMSO_U2932_12_TH001_NG_101118_07_H12

description:
tumor cell line
Therasis_Plate14_TH001_NG_20101118_07_H12

value: DMSO


title: Primary tumor breast - BCPT0130

description: Some arrays correspond to multiple study subjects, which is indicated by the setnr/case-control status


title: Primary tumor breast - BCPT0966


title: Primary tumor breast - BCPT0686


title: Primary tumor breast - BCPT0402


title: Primary tumor breast - BCPT0490


title: Primary tumor breast - BCPT0626


title: TINIDAZOLE_U2932_12_TH001_NG_101118_07_H06

description:
tumor cell line
Therasis_Plate14_TH001_NG_20101118_07_H06

value: TINIDAZOLE


title: FELODIPINE_U2932_12_TH001_NG_101118_07_H10

description:
tumor cell line
Therasis_Plate14_TH001_NG_20101118_07_H10

value: FELODIPINE


title: Primary tumor breast - BCPT0771


title: Primary tumor breast - BCPT0984

value: validation


title: Primary tumor breast - BCPT0501


title: Primary tumor breast - BCPT0946


title: PENTOXIFYLLINE_U2932_12_TH001_NG_101118_07_H09

description:
tumor cell line
Therasis_Plate14_TH001_NG_20101118_07_H09

value: PENTOXIFYLLINE


title: INDAPAMIDE_U2932_12_TH001_NG_101118_07_H04

description:
tumor cell line
Therasis_Plate14_TH001_NG_20101118_07_H04

value: INDAPAMIDE


title: Primary tumor breast - BCPT0014


title: Primary tumor breast - BCPT0319


title: DMSO_U2932_12_TH001_NG_101118_07_H01

description:
tumor cell line
Therasis_Plate14_TH001_NG_20101118_07_H01


title: RIBAVIRIN_U2932_12_TH001_NG_101118_07_H08

description:
tumor cell line
Therasis_Plate14_TH001_NG_20101118_07_H08

value: RIBAVIRIN


title: Primary tumor breast - BCPT0258

value: discovery


title: Primary tumor breast - BCPT0707


title: DAPSONE_U2932_12_TH001_NG_101118_07_H02

description:
tumor cell line
Therasis_Plate14_TH001_NG_20101118_07_H02

value: DAPSONE


title: PROMAZINE.HYDROCHLORIDE_U2932_12_TH001_NG_101118_07_H05

description:
tumor cell line
Therasis_Plate14_TH001_NG_20101118_07_H05


title: Gemcitabine_U2932_12_TH001_NG_101118_07_H07

description:
tumor cell line
Therasis_Plate14_TH001_NG_20101118_07_H07

value: Gemcitabine


title: VALPROIC.ACID_U2932_12_TH001_NG_101118_07_G12

description:
tumor cell line
Therasis_Plate14_TH001_NG_20101118_07_G12


title: Toremifene_U2932_12_TH001_NG_101118_07_G11

description:
tumor cell line
Therasis_Plate14_TH001_NG_20101118_07_G11

value: Toremifene


title: Butoconazole.nitrate_U2932_12_TH001_NG_101118_07_G10

description:
tumor cell line
Therasis_Plate14_TH001_NG_20101118_07_G10


title: ALTRETAMINE_U2932_12_TH001_NG_101118_07_G06

description:
tumor cell line
Therasis_Plate14_TH001_NG_20101118_07_G06

value: ALTRETAMINE


title: Primary tumor breast - BCPT0953

value: Primary tumor breast


title: Primary tumor breast - BCPT0547


title: Primary tumor breast - BCPT0957


title: Primary tumor breast - BCPT0107


title: Primary tumor breast - BCPT0633


title: Primary tumor breast - BCPT0624


title: CYTARABINE_U2932_12_TH001_NG_101118_07_G08

description:
tumor cell line
Therasis_Plate14_TH001_NG_20101118_07_G08

value: CYTARABINE


title: HYDROCHLOROTHIAZIDE_U2932_12_TH001_NG_101118_07_G04

description:
tumor cell line
Therasis_Plate14_TH001_NG_20101118_07_G04

value: HYDROCHLOROTHIAZIDE


title: INDOMETHACIN_U2932_12_TH001_NG_101118_07_G03

description:
tumor cell line
Therasis_Plate14_TH001_NG_20101118_07_G03

value: INDOMETHACIN


title: Primary tumor breast - BCPT0027

description: Some arrays correspond to multiple study subjects, which is indicated by the setnr/case-control status


title: Primary tumor breast - BCPT0119


title: Primary tumor breast - BCPT0293